FDA Issues Not Approvable Letter for Gepirone ER
Posted on: Monday, 5 November 2007, 12:00 CST
Fabre-Kramer Pharmaceuticals and GlaxoSmithKline have announced that the Food and Drug Administration has issued a not approvable letter for a new drug application for gepirone extended release tablets, submitted for the treatment of adults with major depressive disorder.
The Food and Drug Administration (FDA) had previously reviewed Phase I through III clinical data involving gepirone extended release (ER). In June 2004, the FDA requested an additional positive short-term trial in order to consider gepirone ER for approval. Subsequently, Fabre-Kramer (FKP) successfully conducted a trial in patients with major depressive disorder to respond to the FDA request for an additional positive pivotal study.
Those results were submitted to the FDA in May 2007. The not approvable letter issued today is based on the FDA review of those additional results along with other newly submitted and previously submitted data.
Source: Datamonitor
Related Articles
- Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban
- AMAG Pharmaceuticals, Inc. Submits New Drug Application to FDA for Ferumoxytol in Chronic Kidney Disease Patients
- Critical Therapeutics Submits New Drug Application for Controlled-Release Formulation of Zileuton To FDA
- POINT Biomedical Submits New Drug Application (NDA) for CARDIOsphere(R) for the Assessment of Coronary Artery Disease
- AstraZeneca Submits New Drug Application for TOPROL-XL(R)(Metoprolol Succinate)/Hydrochlorothiazide Combination Tablets for the Management of Hypertension
- Eisai Submits New Drug Application to the FDA for Anti-Epileptic Drug Rufinamide
- Abbott Submits New Drug Application to U.S. FDA for Advanced Prostate Cancer Drug, Xinlay(TM) (Atrasentan)
- Neurocrine Submits New Drug Application (NDA) for Indiplon Immediate Release Capsules for the Treatment of Insomnia
 |
 |
User Comments (0)
RSS Feeds